PPARG and kidney disorder: Accumulating evidence suggested that PPARγ agonists could also provide a protection in wider spectrum of kidney diseases, such as the acute nephrotic syndrome, nondiabetic glomerulosclerosis, and the polycystic kidney [96, 97].